Panacea Venture, a life sciences venture fund and new Cure Collaboration Residency company, has invested in more than 30 private companies and several public companies—including those focused on cell and gene therapies, small molecules, biologics, clinical research organizations, medical devices, and diagnostics—and has incubated or started about a third of them. Read more from James Huang, MBA, Managing Partner at Panacea Ventures, regarding the company's mission and the advantages of being part of the Cure. ecosystem. https://lnkd.in/ecrsW_hx
About us
Cure is a vibrant healthcare innovation campus in the heart of New York City with a mission to advance health. Supporting healthcare and life science entrepreneurs, Cure offers digital and in-person content, programming, and learnings on critical health and business topics. The campus at 345 Park Avenue South features laboratory and business facilities, office space and premium event venues, including an education center, conference center, and iconic rooftop terrace. Residents and members collaborate across the spectrum of healthcare and focus on diagnostic, device, drug development and production as well as care delivery and public health. For more information, please visit wewillcure.com.
- Website
-
www.wewillcure.com
External link for Cure.
- Industry
- Health and Human Services
- Company size
- 11-50 employees
- Headquarters
- New York, NY
- Type
- Privately Held
- Founded
- 2020
- Specialties
- Life Science, Incubator, Fellowships, healthcare, scientists, doctors, researchers, digitalhealth, science, health, startup, doctors , ecosystems, business, AI, education, cancer, entreprenuer, health equity, access to care, global health, artificial intelligence, events, and start-ups
Locations
-
Primary
345 Park Ave S
New York, NY 10010, US
Employees at Cure.
-
David Ewing Duncan
Journalist, Author, Researcher, Curator, and Advisor
-
Lauren Ruotolo
Creative Media Partnerships & Executive Producer | Keynote Speaker | Disability Advocate
-
Paul Oestreicher
Strategic Communications; Public and Media Relations; Risk/Issues/Crisis/Reputation Management; Thought Leader; Mentor, and Trusted…
-
Charles Kim
COO & CFO | Healthcare, Sustainability, Food & Beverage
Updates
-
Tomorrow, join us for Tuesday's talks with guest Susan Hockfield, PhD, Massachusetts Institute of Technology's first female president. She'll discuss the shared innovation mission of Kendall Square and MIT and its impact on life science entrepreneurship. Hockfield will share insights from her trailblazing leadership of MIT, including strengthening its synergies with Kendall Square’s thriving biotech and tech industries. The discussion will include lessons learned from Hockfield’s projects, like the MIT Energy Initiative, that tackled global challenges and solidified the area as a powerhouse of transformative innovation. REGISTER TODAY!
Partnering to Innovate: Kendall Square & MIT
www.linkedin.com
-
#ICYMI: Watch this episode of Tuesday Talks, where we discussed whether AI can revolutionize medicine by enhancing drug development efficiency, accuracy, and cost-effectiveness. Cure and The New York Academy of Sciences with Nicholas Dirks brought together a panel of experts, including George Church of Harvard University, Maria Luisa Pineda, PhD. of Envisagenics, Grant W Mitchell, MD, MBA, of Every Cure, and Thomas Fuchs of Icahn School of Medicine at Mount Sinai who discussed AI's transformative role in bringing patients more effective treatments faster. #aiforgood #wewillcure
www.linkedin.com
-
Cure asked Jessica J. Federer, MPH, if we have sufficient data on women's health or if a significant gender gap still exists. Watch to uncover the alarming data gaps in women's healthcare research. #womenshealth #gendergap #biofuture2024
-
Sergei Petukhov, DVM co-founder and CEO of Metallomix Inc. a Cure resident company that is developing disease-modifying drugs based on isotopically modified zinc for the treatment of diseases such as cancer, neurodegenerative diseases and metabolic disorders. Read more to find out Petukhov’s five essential tips for biotech entrepreneurs on building a resilient company. https://lnkd.in/dvc5RNW8
Pioneering Biotech Metallomix’s Strategic Advice for Startups
wewillcure.com
-
Greg Simon the former leader of President Biden's Cancer Moonshot, believes that saving lives depends less on new technologies and more on effective access to existing ones. Read more to discover his insights on what the future of the healthcare market might look like. https://lnkd.in/ezdar-qE
Simon Calls for Healthcare Reform Focused on Accessibility
wewillcure.com
-
With women representing 51% of the U.S. population, why does their healthcare continue to lag in technology, policy, and education? Join us next week for Tuesday Talks with the inspiring Jessica J. Federer, MPH, a globally recognized leader in digital transformation and health technologies! Cure CEO Seema Kumar sat down with Jessica during #biofuture2024, produced by Demy-Colton, to discuss the critical challenges that still stand in the way of true progress in women’s health research. Don’t miss this eye-opening conversation! #linkedinlive #womenshealth
Tuesday Talks: The Real Challenges of the Healthcare Research Gender Gap
www.linkedin.com
-
Stephen Klasko, Executive In Residence at General Catalyst is transforming health equity and payer-provider relationships by risk-taking, creating new partnerships, and shifting current cultures. Read more: https://lnkd.in/efy8nbmS
Stephen Klasko on Disrupting Healthcare Systems to Improve
wewillcure.com
-
#ICYMI, Watch Kevin J. Tracey, MD, the founding father of bioelectronic medicine and the President of The Feinstein Institutes at Northwell Health. Cure CEO Seema Kumar sat down with Tracey during #biofuture2024, produced by Demy-Colton, where he discussed the latest advances in bioelectronic medicine and how these innovations could transform disease management using electrical pulses instead of drugs. Watch Now!
ICYMI: Why Bioelectronic Medicine Could Transform Chronic Disease Treatment
www.linkedin.com